LANN-study: Lantus, Amaryl, Novorapid, Novomix Study

Status Completed

Clinical Trial Summary

Many diabetics gain weight while on insulin therapy. In this study, we evaluate the efficacy of the combination of glimepiride and short-acting insulin on weight control and glucose control. In this study, 150 diabetics whose diabetic control is inadequate while on maximal oral treatment will be randomized to either the new combination treatment or twice daily injections with a mixture of short- and longacting insulin or once-daily injection with a basal insulin analog. The study will compare glucose control and weight gain during a year after randomisation between the three treatments.

Clinical Trial Description

Diabetic patients failing on maximal oral treatment usually switch to twice daily administration of a mixture of short- and longacting insulin. Although this improves glycemic control, it is generally accompanied by a substantial gain in body weight. This may lead to an increase in body fat resulting in a worsening of insulin resistance, leading to an increase in insulin dose needed to maintain glycemic control.

The combination of glimepiride(amaryl) and short-acting insulin (novorapid) is thought to attain glycemic control with a smaller increase in body weight.

In this randomized controlled trial, 150 diabetics failing on maximal oral treatment will be randomized to preprandial use of Novorapid combined with Amaryl at 20.00 hours, twice daily Novomix 30, or once daily Lantus. Metformin will be continued.

In the year after randomisation, patients will be followed for glycemic control, body weight, body composition, recorded number of hypoglycemic events, plasma lipid levels, basal and stimulated C-peptide levels and adverse effects. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00151697
Study type	Interventional
Source	Rijnstate Hospital
Contact
Status	Completed
Phase	Phase 3
Start date	May 2005

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT02261545` - The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient	Phase 4
Completed	`NCT02028091` - Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements	N/A
Completed	`NCT01684813` - VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel	Phase 4
Completed	`NCT01252524` - Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study	N/A
Recruiting	`NCT01311401` - Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel	N/A
Completed	`NCT00563225` - 20 Week Bridging Study in Type II DM	Phase 3
Recruiting	`NCT01565096` - Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy	Phase 4
Withdrawn	`NCT01453751` - Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes	N/A
Not yet recruiting	`NCT01775059` - Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4	N/A
Completed	`NCT01281098` - Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.	Phase 2
Completed	`NCT01669473` - A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use	N/A
Completed	`NCT02036372` - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus	N/A
Completed	`NCT03258840` - EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus	N/A
Active, not recruiting	`NCT01386801` - Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana	N/A
Completed	`NCT02144948` - Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II	Phase 3